Pudafensine, a CNS-acting candidate, has shown efficacy and safety in sexual dysfunction and pain, with a Phase II vulvodynia trial set to start in the UK by late 2025. Strong financial backing and strategic partnerships support expansion into high-need markets.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.